 Home > Biochemistry News > Microbiology News > The research results of Bifidobacterium lactis Probio-M8 on asthma symptoms were published in an international authoritative journal

The research results of Bifidobacterium lactis Probio-M8 on asthma symptoms were published in an international authoritative journal

 Last Update: 2021-11-01
 Source: Internet
 Author: User

Tags

keppra blood level

environmental working group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In October 2021, the latest research results of Ketuo Bio's star strain Bifidobacterium lactis Probio-M8 on the relief of asthma symptoms were successfully published in the international authoritative journal "Microbiology Spectrum" (IF=7.
171)
.
This project is led by the team of Professor Zhang Heping, chief scientist of Ketuo Biology, conducted in Weihai Municipal Hospital of Shandong Province on the probiotic Bifidobacterium lactis Probio-M8 for the relief of asthma symptoms.
Bifidobacterium Probio-M8 can relieve asthma symptoms
.
"Microbiology Spectrum" is a well-known journal in the field of international microbiology.
The successful publication of the related research results of Bifidobacterium lactis Probio-M8 indicates that the star strains of Ketuo Bio are going to the world, and it is also related to the level of research and transformation of China's probiotic industry.
Affirmation of working hard!
Asthma, as a chronic respiratory disease with high morbidity and mortality in the world, plagues many patients, and its etiology is related to many factors
.
Studies have shown that the imbalance of the microbiota can aggravate the occurrence of lung inflammation and asthma-related symptoms; while probiotics have shown anti-inflammatory effects and can effectively regulate the "gut-lung axis"
.
Animal experiments show that supplementing with probiotics can regulate the intestinal flora and prevent and relieve asthma symptoms
.
Bifidobacterium lactis Probio-M8, which is derived from breast milk, is a strain with excellent probiotic properties.
Previous studies have shown that it is helpful in the regulation of intestinal flora and immune regulation! Therefore, this study explored the probiotic Bifidobacterium lactis Probio-M8 for the relief of asthma symptoms in humans
.

The research team selected 55 asthma patients from Weihai Municipal Hospital in Shandong Province to participate in a 3-month clinical trial and randomly divided them into a probiotic group (daily taking 2 grams of Bifidobacterium lactis Probio-M8 30 billion CFU and drug Xinbi be) or placebo (the same amount of drug and placebo Symbicort) study, clinical index periodically asthma, stool samples, blood samples, and detection and acquisition
.

The results showed that after the intervention of probiotics, the concentration of nitric oxide and exhaled nitric oxide in the alveoli of asthma patients decreased significantly, and the asthma control (ACT) score increased significantly, and the improvement effect was more obvious after 3 months of continuous use
.
Bifidobacterium lactis Probio-M8 is also well tolerated.
It can smoothly pass through the digestive tract to the intestine, regulate the intestinal flora, and has auxiliary effects in regulating specific biologically active metabolites and related pathways
.
The intervention of Bifidobacterium lactis Probio-M8 can significantly increase the level of metabolites such as dodecanoic acid, intestinal diol, tryptophan and sphingomyelin in the blood, thereby inhibiting the signal pathway to exert anti-inflammatory effects and participate in immune regulation to improve clinical Curative effect
.

This indicates that the drug Symbico combined with Bifidobacterium lactis Probio-M8 can effectively relieve the symptoms of asthma
.
While Bifidobacterium lactis Probio-M8 regulates the intestinal flora through the "gut-lung axis", it can also regulate the content of biologically active substances in the serum metabolome, participate in immune regulation, and have anti-inflammatory effects, thereby improving clinical asthma.
symptom!
　　Ketuo Biotech has always adhered to scientific research and continuous innovation, and has built a strain resource bank that preserves 20,000 strains of lactic acid bacteria
.
The publication of the research results of Bifidobacterium lactis Probio-M8 on the alleviation of asthma symptoms marks a new breakthrough in the exploration of the probiotic effects of Ketuo's strains! Ketuo Biosciences has enriched the research on the probiotic effects of breast milk-derived probiotics; it has also perfected the related research and clinical trials of star strains in the adjuvant treatment of chronic diseases
.

In October 2021, the latest research results of Ketuo Bio's star strain Bifidobacterium lactis Probio-M8 on the relief of asthma symptoms were successfully published in the international authoritative journal "Microbiology Spectrum" (IF=7.
171)
.
This project is led by the team of Professor Zhang Heping, chief scientist of Ketuo Biology, conducted in Weihai Municipal Hospital of Shandong Province on the probiotic Bifidobacterium lactis Probio-M8 for the relief of asthma symptoms.
Bifidobacterium Probio-M8 can relieve asthma symptoms
.
"Microbiology Spectrum" is a well-known journal in the field of international microbiology.
The successful publication of the related research results of Bifidobacterium lactis Probio-M8 indicates that the star strains of Ketuo Bio are going to the world, and it is also related to the level of research and transformation of China's probiotic industry.
Affirmation of working hard!
　　Asthma, as a chronic respiratory disease with high morbidity and mortality in the world, plagues many patients, and its etiology is related to many factors
.
Studies have shown that the imbalance of the microbiota can aggravate the occurrence of lung inflammation and asthma-related symptoms; while probiotics have shown anti-inflammatory effects and can effectively regulate the "gut-lung axis"
.
Animal experiments show that supplementing with probiotics can regulate the intestinal flora and prevent and relieve asthma symptoms
.
Bifidobacterium lactis Probio-M8, which is derived from breast milk, is a strain with excellent probiotic properties.
Previous studies have shown that it is helpful in the regulation of intestinal flora and immune regulation! Therefore, this study explored the probiotic Bifidobacterium lactis Probio-M8 for the relief of asthma symptoms in humans
.

　　The research team selected 55 asthma patients from Weihai Municipal Hospital in Shandong Province to participate in a 3-month clinical trial and randomly divided them into a probiotic group (daily taking 2 grams of Bifidobacterium lactis Probio-M8 30 billion CFU and drug Xinbi be) or placebo (the same amount of drug and placebo Symbicort) study, clinical index periodically asthma, stool samples, blood samples, and detection and acquisition
.

　　The results showed that after the intervention of probiotics, the concentration of nitric oxide and exhaled nitric oxide in the alveoli of asthma patients decreased significantly, and the asthma control (ACT) score increased significantly, and the improvement effect was more obvious after 3 months of continuous use
.
Bifidobacterium lactis Probio-M8 is also well tolerated.
It can smoothly pass through the digestive tract to the intestine, regulate the intestinal flora, and has auxiliary effects in regulating specific biologically active metabolites and related pathways
.
The intervention of Bifidobacterium lactis Probio-M8 can significantly increase the level of metabolites such as dodecanoic acid, intestinal diol, tryptophan and sphingomyelin in the blood, thereby inhibiting the signal pathway to exert anti-inflammatory effects and participate in immune regulation to improve clinical Curative effect
.

This indicates that the drug Symbico combined with Bifidobacterium lactis Probio-M8 can effectively relieve the symptoms of asthma
.
While Bifidobacterium lactis Probio-M8 regulates the intestinal flora through the "gut-lung axis", it can also regulate the content of biologically active substances in the serum metabolome, participate in immune regulation, and have anti-inflammatory effects, thereby improving clinical asthma.
symptom!
　　Ketuo Biotech has always adhered to scientific research and continuous innovation, and has built a strain resource bank that preserves 20,000 strains of lactic acid bacteria
.
The publication of the research results of Bifidobacterium lactis Probio-M8 on the alleviation of asthma symptoms marks a new breakthrough in the exploration of the probiotic effects of Ketuo's strains! Ketuo Biosciences has enriched the research on the probiotic effects of breast milk-derived probiotics; it has also perfected the related research and clinical trials of star strains in the adjuvant treatment of chronic diseases
.

Disclaimer: This article only represents the author's personal views and has nothing to do with China Probiotics.
com
.
The originality and the text and content stated in the article have not been verified by this site.
This site does not make any guarantee or commitment to the authenticity, completeness, and timeliness of this article, all or part of the content, and the text.
Please readers for reference only, and please Verify the relevant content yourself
.

Copyright Notice
1.
Some of the reprinted articles on this site are not original, and the copyright and liability belong to the original author
.
2.
All reprinted articles, links and pictures on this website are for the purpose of conveying more information, and clearly indicate the source and author.
Media or individuals who do not want to be reprinted can contact us for infringement information that can provide sufficient evidence , Bio149 will be deleted within 12 hours after confirmation
.
3.
Users are welcome to post original articles to 86371366@qq.
com, and publish them to the homepage after review.
The copyright and liability belong to the sender
.

In October 2021, the latest research results of Ketuo Bio's star strain Bifidobacterium lactis Probio-M8 on the relief of asthma symptoms were successfully published in the international authoritative journal "Microbiology Spectrum" (IF=7.
171)
.
This project is led by the team of Professor Zhang Heping, chief scientist of Ketuo Biology, conducted in Weihai Municipal Hospital of Shandong Province on the probiotic Bifidobacterium lactis Probio-M8 for the relief of asthma symptoms.
Bifidobacterium Probio-M8 can relieve asthma symptoms
.
"Microbiology Spectrum" is a well-known journal in the field of international microbiology.
The successful publication of the related research results of Bifidobacterium lactis Probio-M8 indicates that the star strains of Ketuo Bio are going to the world, and it is also related to the level of research and transformation of China's probiotic industry.
Affirmation of working hard!
　　Asthma, as a chronic respiratory disease with high morbidity and mortality in the world, plagues many patients, and its etiology is related to many factors
.
Studies have shown that the imbalance of the microbiota can aggravate the occurrence of lung inflammation and asthma-related symptoms; while probiotics have shown anti-inflammatory effects and can effectively regulate the "gut-lung axis"
.
Animal experiments show that supplementing with probiotics can regulate the intestinal flora and prevent and relieve asthma symptoms
.
Bifidobacterium lactis Probio-M8, which is derived from breast milk, is a strain with excellent probiotic properties.
Previous studies have shown that it is helpful in the regulation of intestinal flora and immune regulation! Therefore, this study explored the probiotic Bifidobacterium lactis Probio-M8 for the relief of asthma symptoms in humans
.

　　The research team selected 55 asthma patients from Weihai Municipal Hospital in Shandong Province to participate in a 3-month clinical trial and randomly divided them into a probiotic group (daily taking 2 grams of Bifidobacterium lactis Probio-M8 30 billion CFU and drug Xinbi be) or placebo (the same amount of drug and placebo Symbicort) study, clinical index periodically asthma, stool samples, blood samples, and detection and acquisition
.

　　The results showed that after the intervention of probiotics, the concentration of nitric oxide and exhaled nitric oxide in the alveoli of asthma patients decreased significantly, and the asthma control (ACT) score increased significantly, and the improvement effect was more obvious after 3 months of continuous use
.
Bifidobacterium lactis Probio-M8 is also well tolerated.
It can smoothly pass through the digestive tract to the intestine, regulate the intestinal flora, and has auxiliary effects in regulating specific biologically active metabolites and related pathways
.
The intervention of Bifidobacterium lactis Probio-M8 can significantly increase the level of metabolites such as dodecanoic acid, intestinal diol, tryptophan and sphingomyelin in the blood, thereby inhibiting the signal pathway to exert anti-inflammatory effects and participate in immune regulation to improve clinical Curative effect
.

This indicates that the drug Symbico combined with Bifidobacterium lactis Probio-M8 can effectively relieve the symptoms of asthma
.
While Bifidobacterium lactis Probio-M8 regulates the intestinal flora through the "gut-lung axis", it can also regulate the content of biologically active substances in the serum metabolome, participate in immune regulation, and have anti-inflammatory effects, thereby improving clinical asthma.
symptom!
　　Ketuo Biotech has always adhered to scientific research and continuous innovation, and has built a strain resource bank that preserves 20,000 strains of lactic acid bacteria
.
The publication of the research results of Bifidobacterium lactis Probio-M8 on the alleviation of asthma symptoms marks a new breakthrough in the exploration of the probiotic effects of Ketuo's strains! Ketuo Biosciences has enriched the research on the probiotic effects of breast milk-derived probiotics; it has also perfected the related research and clinical trials of star strains in the adjuvant treatment of chronic diseases
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.